HomeCompareBRQS vs MRK

BRQS vs MRK: Dividend Comparison 2026

BRQS yields 465.12% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRQS wins by $35260.42M in total portfolio value
10 years
BRQS
BRQS
● Live price
465.12%
Share price
$0.43
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35260.48M
Annual income
$24,780,059,848.68
Full BRQS calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — BRQS vs MRK

📍 BRQS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRQSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRQS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRQS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRQS
Annual income on $10K today (after 15% tax)
$39,534.88/yr
After 10yr DRIP, annual income (after tax)
$21,063,050,871.38/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, BRQS beats the other by $21,063,042,274.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRQS + MRK for your $10,000?

BRQS: 50%MRK: 50%
100% MRK50/50100% BRQS
Portfolio after 10yr
$17630.27M
Annual income
$12,390,034,981.23/yr
Blended yield
70.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BRQS
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-4.1
Piotroski
5/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRQS buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRQSMRK
Forward yield465.12%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$35260.48M$57.7K
Annual income after 10y$24,780,059,848.68$10,113.78
Total dividends collected$34333.38M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: BRQS vs MRK ($10,000, DRIP)

YearBRQS PortfolioBRQS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$57,212$46,511.63$11,213$373.04+$46.0KBRQS
2$309,909$248,692.14$12,667$512.06+$297.2KBRQS
3$1,590,608$1,259,005.40$14,439$708.14+$1.58MBRQS
4$7,741,065$6,039,114.42$16,640$988.16+$7.72MBRQS
5$35,750,944$27,468,005.00$19,432$1,394.07+$35.73MBRQS
6$156,811,320$118,557,809.37$23,057$1,992.90+$156.79MBRQS
7$653,788,128$486,000,015.63$27,889$2,894.79+$653.76MBRQS
8$2,593,257,425$1,893,704,128.62$34,518$4,286.29+$2593.22MBRQS
9$9,794,782,802$7,019,997,357.51$43,912$6,494.35+$9794.74MBRQS
10$35,260,477,447$24,780,059,848.68$57,714$10,113.78+$35260.42MBRQS

BRQS vs MRK: Complete Analysis 2026

BRQSStock

Borqs Technologies, Inc. provides Android-based smart connected devices and cloud service solutions in the United States, India, China, and internationally. The company offers commercial grade Android platform software and service solutions to address vertical market segment needs through the targeted BorqsWare software platform solutions. Its BorqsWare software platform consists of BorqsWare Client software that has been used in Android phones, tablets, watches, and various Internet-of-things devices; and BorqsWare Server software platform, which includes back-end server software that allows customers to develop their own mobile end-to-end services for their devices. In addition, it provides IVI solutions, machine to machine solutions, smart appliance solution, mobile operator services, and google mobile services (GMS). The company primarily serves mobile chipset manufacturers, mobile device original equipment manufacturers, and mobile operators, as well as product solutions of mobile connected devices for enterprise and consumer applications. Borqs Technologies, Inc. was founded in 2007 and is headquartered in Kwun Tong, Hong Kong.

Full BRQS Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this BRQS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRQS vs SCHDBRQS vs JEPIBRQS vs OBRQS vs KOBRQS vs MAINBRQS vs JNJBRQS vs ABBVBRQS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.